GeoVax Labs (NASDAQ:GOVX) Announces Quarterly Earnings Results, Beats Estimates By $1.19 EPS

GeoVax Labs (NASDAQ:GOVX) issued its quarterly earnings data on Monday. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($2.16) by $1.19, FiscalAI reports.

GeoVax Labs Stock Performance

GOVX traded up $0.03 on Monday, reaching $0.76. The company had a trading volume of 166,250 shares, compared to its average volume of 2,345,560. GeoVax Labs has a 52-week low of $0.69 and a 52-week high of $20.62. The company has a market cap of $2.64 million, a price-to-earnings ratio of -0.04 and a beta of 3.68. The business has a 50 day simple moving average of $1.55 and a 200 day simple moving average of $1.84.

Hedge Funds Weigh In On GeoVax Labs

A number of institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in shares of GeoVax Labs during the 4th quarter valued at $99,000. HRT Financial LP bought a new position in GeoVax Labs in the fourth quarter valued at $31,000. Renaissance Technologies LLC bought a new position in GeoVax Labs in the fourth quarter valued at $104,000. Finally, Armistice Capital LLC purchased a new stake in GeoVax Labs during the third quarter valued at about $253,000. Institutional investors own 6.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a research report on Thursday, April 16th. Finally, Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, GeoVax Labs currently has a consensus rating of “Reduce” and an average target price of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.